GLAUKOS Corp (GKOS) Q3 2025 10-Q Quarterly Report
Filed: Oct 31, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR GLAUKOS Corp (GKOS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
GLAUKOS Corp Q3 2025 10-Q Analysis
Risk Factors
- • New risk: MIGS restrictions by five MACs limiting iStent sales volume, impacting U.S. glaucoma product revenue growth
- • Updated operational risk: $80M+ planned capital expenditure for new Huntsville, AL R&D and manufacturing facility starting 2026
GLAUKOS Corp Q3 2025 Quarterly FinancialsXBRL
Revenue
$134M
▲ +38.1% YoY▲ +7.6% QoQ
Net Income
-$16M
▲ +24.2% YoY▲ +17.4% QoQ
Gross Margin
78.4%
▲ +177bp YoY▲ +8bp QoQ
Operating Margin
-12.3%
▲ +1325bp YoY▲ +602bp QoQ
Net Margin
-12.2%
▲ +999bp YoY▲ +368bp QoQ
ROE
-2.1%
Total Assets
$999M
EPS (Diluted)
$-0.29
▲ +19.4% YoY▲ +14.7% QoQ
Operating Cash Flow
-$10M
▼ -5.3% YoY▼ -244.6% QoQ
Source: XBRL data from GLAUKOS Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on GLAUKOS Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.